Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG; FEMIMS Group.

Mult Scler. 2008 Nov;14(9):1225-33. doi: 10.1177/1352458508094882. Epub 2008 Aug 13.

PMID:
18701568
2.

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE.

Neurology. 2002 Sep 24;59(6):909-13.

PMID:
12297576
3.

The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R.

Am J Clin Oncol. 2007 Apr;30(2):126-32.

PMID:
17414460
4.

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.

Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.

J Neurol Sci. 2008 Mar 15;266(1-2):25-30. Epub 2007 Sep 17.

PMID:
17870094
5.

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Wiertlevski S, Defer G, Gout O, Berthier F, Danzon A.

Mult Scler. 2008 Apr;14(3):399-405. doi: 10.1177/1352458507083625.

PMID:
18420778
6.

Do estroprogestinic hormones protect against chemotherapy-induced amenorrhea in multiple sclerosis?

Voskuhl R, Wu TC.

Nat Clin Pract Neurol. 2009 Jan;5(1):18-9. doi: 10.1038/ncpneuro0951. Epub 2008 Nov 25.

7.

Mitoxantrone treatment of multiple sclerosis: safety considerations.

Cohen BA, Mikol DD.

Neurology. 2004 Dec 28;63(12 Suppl 6):S28-32. Review.

PMID:
15623667
8.

[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].

Ory S, Debouverie M, Le Page E, Pelletier J, Malikova I, Gout O, Roullet E, Vermersch P, Edan G.

Rev Neurol (Paris). 2008 Dec;164(12):1028-34. doi: 10.1016/j.neurol.2008.04.008. Epub 2008 Jun 9. French.

PMID:
18808781
9.

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Ellis R, Boggild M.

Mult Scler. 2009 Apr;15(4):505-8. doi: 10.1177/1352458508100967. Epub 2009 Feb 27.

PMID:
19251838
10.

The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.

Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME.

Lupus. 2013 Jan;22(1):81-6. doi: 10.1177/0961203312468624.

PMID:
23263867
11.

[Immunosuppressive therapy of multiple sclerosis with mitoxantrone].

Mauch E, Kornhuber HH.

Fortschr Neurol Psychiatr. 1993 Dec;61(12):410-7. German.

PMID:
8112704
12.

[Mitoxantrone for the treatment of patients with multiple sclerosis].

Komori M, Kondo T, Tanaka M.

Brain Nerve. 2009 May;61(5):575-80. Review. Japanese.

PMID:
19514518
13.

Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.

Funch D, Norman H, Wong J, Bennett R, Hillier J, Al-Sabbagh A, Seeger JD.

Pharmacoepidemiol Drug Saf. 2010 May;19(5):448-56. doi: 10.1002/pds.1918.

PMID:
20333778
14.

Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.

Zecca C, Petrini L, Limoni C, Staedler C, Gobbi C.

Eur Neurol. 2011;65(1):40-5. doi: 10.1159/000323013. Epub 2010 Dec 22.

PMID:
21196739
15.

Mitoxantrone for multiple sclerosis in clinical practice.

Rizvi SA, Zwibel H, Fox EJ.

Neurology. 2004 Dec 28;63(12 Suppl 6):S25-7. Review.

PMID:
15623666
16.

Leukaemia due to mitoxantrone.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):153-6.

PMID:
17724842
17.

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.

Zingler VC, Nabauer M, Jahn K, Gross A, Hohlfeld R, Brandt T, Strupp M.

Eur Neurol. 2005;54(1):28-33. Epub 2005 Jul 27.

PMID:
16088176
18.

Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

Singhal BS, Geeta S, Hundalani SG, Menon S.

Neurol India. 2009 Jul-Aug;57(4):418-23. doi: 10.4103/0028-3886.55611.

19.

The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

Murray TJ.

Expert Opin Drug Saf. 2006 Mar;5(2):265-74. Review.

PMID:
16503747
20.

Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.

Buttmann M, Seuffert L, M├Ąder U, Toyka KV.

Neurology. 2016 Jun 7;86(23):2203-7. doi: 10.1212/WNL.0000000000002745. Epub 2016 May 11.

Supplemental Content

Support Center